These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 21291348

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Overactive bladder: diagnosis and management.
    Robinson D, Cardozo L.
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [Abstract] [Full Text] [Related]

  • 6. Darifenacin in the treatment of overactive bladder.
    Parsons M, Robinson D, Cardozo L.
    Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK, De Wachter SG, van Kerrebroeck PE.
    Urol Int; 2010 Jul; 84(3):245-53. PubMed ID: 20389150
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS.
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 14. Redefining response in overactive bladder syndrome.
    Payne CK, Kelleher C.
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [Abstract] [Full Text] [Related]

  • 15. [Medical treatment of voiding problems in men].
    Andersen JT, Nordling J, Walter S.
    Ugeskr Laeger; 2007 May 14; 169(20):1892-4. PubMed ID: 17553364
    [Abstract] [Full Text] [Related]

  • 16. The medical treatment of overactive bladder, including current and future treatments.
    Athanasopoulos A, Cruz F.
    Expert Opin Pharmacother; 2011 May 14; 12(7):1041-55. PubMed ID: 21299469
    [Abstract] [Full Text] [Related]

  • 17. Overactive bladder: an update.
    Hashim H, Abrams P.
    Curr Opin Urol; 2007 Jul 14; 17(4):231-6. PubMed ID: 17558264
    [Abstract] [Full Text] [Related]

  • 18. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE.
    Eur Urol; 2011 Mar 14; 59(3):377-86. PubMed ID: 21168951
    [Abstract] [Full Text] [Related]

  • 19. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP, Laramée C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S.
    Int J Clin Pract; 2008 Jan 14; 62(1):39-46. PubMed ID: 18036164
    [Abstract] [Full Text] [Related]

  • 20. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S, Oo N.
    J Obstet Gynaecol; 2012 Apr 14; 32(3):217-21. PubMed ID: 22369391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.